Pular para o conteúdo
Menu
Mix Vale

Tests with new drugs show weight reduction of more than 25% and advance towards regulatory approval

Luís Henrique Costa
Por 7 min de leitura
Compartilhe
GLP-1 canetas
Foto: GLP-1 canetas - Edugrafo/shutterstock.com

The pharmaceutical industry is going through a period of accelerated transformation in the development of therapies aimed at controlling obesity and associated metabolic diseases. Dados recent advanced clinical trials indicate the imminent arrival of a new class of medications, designed to offer weight loss results that could double the effectiveness of therapeutic options available to date. The substances in the final phase of analysis, which include more complex mechanisms of action than traditional GLP-1 agonists, bring clinical outcomes closer to the numbers historically obtained only through invasive surgical interventions, such as bariatric surgery.

Publicidade

Leading companies in the sector, such as Eli Lilly and Novo Nordisk, have intensified their regulatory races to validate compounds that act on multiple hormonal pathways simultaneously. Enquanto Previous treatments mostly focused on a single receptor to induce satiety, the new molecules seek to mimic the action of two or even three natural hormones in the human body. Essa multifaceted approach has demonstrated, in phase 3 studies, the ability to reduce patients’ body weight by 23% to 28% over treatment periods ranging up to 68 weeks, establishing a new standard of effectiveness for metabolic medicine.

Canetas emagrecedoras e balança
痩身ペンと体重計 – Love Employee/shutterstock.com

The expectation of doctors and specialists is that the introduction of these therapies into the global market will occur in a staggered manner throughout 2026, depending on the final approval from health surveillance agencies. Além the reduction in measures, the focus of research expands to the systemic benefits of these drugs, which include improved glycemic control in patients with type 2 diabetes, the reduction of liver fat and potential cardiovascular benefits. The scenario points to a paradigm shift, where obesity starts to be treated with pharmacological tools of high potency and biological precision.

Publicidade

Retrotrude advances and the triple mechanism of action

One of the most anticipated highlights by the scientific community is the retatrude, developed by Eli Lilly, which inaugurates the “triple agonists” category. Diferente than its predecessors, this molecule was designed to activate receptors for three distinct hormones: GLP-1, GIP and glucagon. The inclusion of glucagon in the equation represents an important technical difference, as this hormone is associated with an increase in the body’s energy expenditure, which complements the appetite suppression action promoted by the other two components.

Preliminary results and consolidated data from mid- and late-phase studies have shown that retatrutide can lead to an average weight loss of more than 26% at higher doses. Esse performance significantly surpasses that of tirzepatide, which acts on two receptors, and semaglutide, which acts on only one. The simultaneous activation of these metabolic pathways suggests that the drug not only reduces caloric intake, but also optimizes the way the body processes and burns energy, offering a robust solution for patients with severe obesity or those resistant to other treatments.

In addition to its effectiveness on the scale, retatrutide has demonstrated a profound impact on liver health. Observações clinics point to a dramatic reduction in liver fat, which could position the drug as a vital tool in combating non-alcoholic fatty liver disease, a condition that often accompanies excess weight and for which there are few direct therapeutic options. The validation of these data follows strict safety protocols to ensure that the drug’s potency is not accompanied by unacceptable adverse effects.

CagriSema combined strategy

In parallel, Novo Nordisk is betting on a fixed combination of two active substances in a single weekly injection, called CagriSema. Este treatment combines semaglutide, already widely known and used, with an amylin analogue called cagrilintide. Amylin is a pancreatic hormone that works in synergy with insulin and plays a crucial role in regulating postprandial satiety, sending “fullness” signals to the brain shortly after eating food.

  • Enhancement of weight loss compared to monotherapy.
  • Dual action focused on different satiety signaling pathways.
  • Preliminary results indicating weight reduction of around 25%.
  • Maintenance of the cardiovascular safety profile observed in the class.

The logic behind CagriSema is to attack obesity from two distinct but complementary biological fronts. Enquanto semaglutide acts mainly on the incretin system, cagrilintide reinforces the satiety message through amylin receptors. Estudos comparisons indicated that this combination surpasses the effectiveness of each isolated component, offering an additional weight loss estimated at between 10 and 14 percentage points in relation to the exclusive use of semaglutide. Essa strategy aims to serve patients who have reached a plateau with current therapies or who require more aggressive intervention to reverse complex metabolic conditions.

Publicidade

Safety considerations and side effects

Despite the optimism generated by the efficacy figures, the introduction of these new drugs requires caution and continuous monitoring regarding safety. The side effect profile observed in clinical trials largely follows the pattern already known for GLP-1 agonists, with a prevalence of gastrointestinal symptoms. Náuseas, vomiting and diarrhea are the most common adverse reactions, especially during the initial dose titration phase, when the body is adapting to the medication.

A central concern of researchers and regulatory agencies is the composition of weight loss. It is essential to ensure that rapid reduction in body mass does not result in excessive loss of lean muscle mass, which could compromise the long-term metabolic health and physical functionality of patients, especially in the elderly. Protocolos treatments that combine the use of these medications with resistance exercise programs and adequate nutrition are seen as essential to mitigate this risk and ensure healthy and sustainable weight loss.

Another point of attention is the sustainability of the treatment. Obesity is recognized as a chronic and relapsing disease, which means that stopping the use of medications can lead to weight regain. Estudos long-term treatments are being conducted to evaluate the safety of continued use of these substances for years or decades, as well as to better understand the body’s adaptation mechanisms and the need for maintenance therapies.

Impact on the market and access to treatment

The expected arrival of these new therapeutic options throughout 2026 is expected to reconfigure the global healthcare market. The pent-up demand for effective treatments against obesity suggests rapid adoption, however, issues related to cost and industrial production capacity remain logistical challenges. Drugmakers have invested billions in expanding their manufacturing capabilities to avoid the shortages that marked the launch of previous generations of weight-loss drugs.

From a clinical point of view, the diversification of the therapeutic arsenal will allow for more personalized medicine. With options ranging from simple agonists to triple combinations, endocrinologists will be able to select the most appropriate drug based on each patient’s metabolic profile, tolerance and specific needs. Isso represents a significant advance over the standardized approach, allowing fine adjustments that can improve treatment adherence and long-term outcomes.

Health economic analyzes also project that despite the high initial cost of drugs, reducing complications associated with obesity—such as heart disease, stroke, and orthopedic problems—could generate substantial savings for health systems in the future. The prevention of major cardiovascular events and the improvement in quality of life are metrics that weigh favorably in evaluating the cost-effectiveness of these new technologies.

Keywords: obesity, drug treatment, GLP-1, weight loss.

Long-tail keywords: new weight loss drugs in 2026.

Links researched:

https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-novo-nordisk-obesity-drugs-2025-2023-10-04/

https://www.nature.com/articles/d41586-023-03034-w

Publicidade

Luís Henrique Costa é jornalista formado pela FMU, editor-chefe e fundador do Mix Vale, portal de notícias em atividade desde 2011. Responde pela direção editorial do veículo, que cobre Brasil e mundo em economia, benefícios sociais, esportes, tecnologia, ciência e entretenimento. Atua na área há mais de 15 anos e lidera uma equipe de cerca de 15 colaboradores.

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto